Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653636 | 0.92 | MRGPRX4 (0.49) | MRGPRX4SLC6A4SMN1; SMN2HPGDNOTUM | |
| SCHEMBL21653635 | 0.86 | MRGPRX4 (0.48) | MRGPRX4SLC6A4SMN1; SMN2HPGDNOTUM | |
| SCHEMBL23677886 | 0.86 | MRGPRX4 (0.51) | MRGPRX4SLC6A4SMN1; SMN2NOTUMKDM4E | |
| SCHEMBL25974302 | 0.85 | FFAR1 (0.46) | SLC6A4SMN1; SMN2USP2KDM4ES1PR4 | |
| SCHEMBL14409236 | 0.83 | HTR2C (0.49) | MRGPRX4SLC6A4USP2NOTUMHTT | |
| SCHEMBL14402360 | 0.83 | HPGD (0.47) | SMN1; SMN2USP2HPGDKDM4EKMT2A | |
| SCHEMBL21601443 | 0.81 | ESR1 (0.49) | MRGPRX4SLC6A4NOTUMKDM4ERAB9A | |
| SCHEMBL15223509 | 0.81 | ESR1 (0.51) | MRGPRX4SLC6A4SMN1; SMN2NOTUMHTT | |
| SCHEMBL10078701 | 0.81 | MRGPRX4 (0.48) | MRGPRX4SLC6A4NOTUMKDM4EL3MBTL1 | |
| SCHEMBL20224817 | 0.81 | MRGPRX4 (0.44) | MRGPRX4SLC6A4SMN1; SMN2HPGDNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| CN-1231465-C | Biphenylsulfonyl cyanamides, method for the production thereof and use thereof as medicaments | AVENTIS PHARMACEUTIC DEUTSCHLA (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| CN-1289321-A | Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament | AVENTIS PHARMACEUTIC DEUTSCHLA (DE) | 2001-03-28 | — | — | CN | disclosed |
| EP-1053224-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040064-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | MRGPRX4 4672/4885SLC6A4 4185/4885SMN1; SMN2 4777/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | MRGPRX4 4724/4885SLC6A4 4246/4885SMN1; SMN2 4852/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | MRGPRX4 4718/4885SLC6A4 3844/4885SMN1; SMN2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.